Plinabulin could 'revolutionize treatment for neutropenia', drugmaker believes

20 December 2016

US immuno-oncology specialist BeyondSpring Pharmaceuticals has presented clinically and statistically significant data on its lead asset plinabulin for the mitigation of chemotherapy-induced neutropenia.

The Phase II data shows that this novel small molecule with immune-enhancing effects and anti-cancer activity that is given by IV infusion one hour after chemotherapy, has the potential to be a safe, cost-effective and convenient alternative to G-CSF, the current standard of care for chemotherapy-induced neutropenia, with much less bone pain and a more favorable safety profile.

"BeyondSpring is moving full speed ahead in developing this innovative, cost-effective therapeutic alternative to G-CSF for cancer patients"

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK